Skip to main content
Erschienen in: Insights into Imaging 1/2021

Open Access 01.12.2021 | Original Article

CT and MRI radiomics of bone and soft-tissue sarcomas: a systematic review of reproducibility and validation strategies

verfasst von: Salvatore Gitto, Renato Cuocolo, Domenico Albano, Francesco Morelli, Lorenzo Carlo Pescatori, Carmelo Messina, Massimo Imbriaco, Luca Maria Sconfienza

Erschienen in: Insights into Imaging | Ausgabe 1/2021

Abstract

Background

Feature reproducibility and model validation are two main challenges of radiomics. This study aims to systematically review radiomic feature reproducibility and predictive model validation strategies in studies dealing with CT and MRI radiomics of bone and soft-tissue sarcomas. The ultimate goal is to promote achieving a consensus on these aspects in radiomic workflows and facilitate clinical transferability.

Results

Out of 278 identified papers, forty-nine papers published between 2008 and 2020 were included. They dealt with radiomics of bone (n = 12) or soft-tissue (n = 37) tumors. Eighteen (37%) studies included a feature reproducibility analysis. Inter-/intra-reader segmentation variability was the theme of reproducibility analysis in 16 (33%) investigations, outnumbering the analyses focused on image acquisition or post-processing (n = 2, 4%). The intraclass correlation coefficient was the most commonly used statistical method to assess reproducibility, which ranged from 0.6 and 0.9. At least one machine learning validation technique was used for model development in 25 (51%) papers, and K-fold cross-validation was the most commonly employed. A clinical validation of the model was reported in 19 (39%) papers. It was performed using a separate dataset from the primary institution (i.e., internal validation) in 14 (29%) studies and an independent dataset related to different scanners or from another institution (i.e., independent validation) in 5 (10%) studies.

Conclusions

The issues of radiomic feature reproducibility and model validation varied largely among the studies dealing with musculoskeletal sarcomas and should be addressed in future investigations to bring the field of radiomics from a preclinical research area to the clinical stage.
Hinweise

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
CT
Computed tomography
ICC
Intraclass correlation coefficient
MRI
Magnetic resonance imaging
PRISMA
Preferred Reporting Items for Systematic reviews and Meta-Analyses

Key points

  • Radiomic studies focused on CT and MRI of musculoskeletal sarcomas were reviewed.
  • Feature reproducibility analysis and model validation strategies varied largely among these studies.
  • Radiomic feature reproducibility was assessed in less than half of the studies.
  • Only 10% of the studies included an independent clinical validation of the model.

Background

Bone and soft-tissue primary malignant tumors or sarcomas are rare entities with several histological subtypes, and each has an incidence < 1/100,000/year [1, 2]. Among them, osteosarcoma is the most common sarcoma of the bone. Along with Ewing sarcoma, it has a higher incidence in the second decade of life, while chondrosarcoma is the most prevalent bone sarcoma in adulthood [1]. The most frequent soft-tissue sarcomas are liposarcoma and leiomyosarcoma [2]. Due to the rarity of these diseases, bone and soft-tissue sarcomas are managed in tertiary sarcoma centers according to current guidelines [1, 2]. Both biopsy and imaging integrate clinical data prior to the beginning of any treatment, with the former representing the reference standard for preoperative diagnosis [1, 2]. However, biopsy may be inaccurate in large, heterogeneous tumors due to sampling errors, and, in turn, inaccurate diagnosis may lead to inadequate treatment and subsequent need for further interventions, with increased morbidity. Additionally, the risk of biopsy tract contamination remains a concern. Imaging already plays a pivotal role in the assessment of bone and soft-tissue sarcomas. Magnetic resonance imaging (MRI) and computed tomography (CT) are employed for local and general staging, respectively [1, 2]. These modalities may certainly benefit from new imaging-based tools such as those based on radiomics, which may potentially provide additional information regarding both diagnosis and prognosis noninvasively [3].
The term “radiomics” derives from a combination of “radio,” referring to medical images and “omics,” which indicates the analysis of high amounts of data representing an entire set of some kind, like genome (genomics) and proteome (proteomics) [3]. Therefore, “radiomics” includes extraction and analysis of large numbers of quantitative parameters, known as radiomic features, from medical images [4]. This technique has recently gained much attention in oncologic imaging as it can potentially quantify tumor heterogeneity, which can be challenging to capture by means of qualitative imaging assessment or sampling biopsies. Particularly, radiomic studies to date have focused on discriminating tumor grades and types before treatment, monitoring response to therapy and predicting outcome [5].
Despite its great potential as a noninvasive tumor biomarker, radiomics still faces challenges preventing its clinical implementation. Two main initiatives have addressed methodological issues of radiomic studies to bridge the gap between academic endeavors and real-life application. In 2017, Lambin et al. proposed the Radiomics Quality Score that details the sequential steps to follow in radiomic pipelines and offers a tool to assess methodological rigor in their implementation [6]. In 2020, the Image Biomarkers Standardization Initiative produced and validated reference values for radiomic features, which enable verification and calibration of different software for radiomic feature extraction [7]. However, numerous challenges still remain to ensure clinical transferability of radiomics. As radiomics is essentially a two-step approach consisting of data extraction and analysis, in the first step (i.e., data extraction), the main challenge is reproducibility of radiomic features, which can be influenced by image acquisition parameters, region of interest segmentation technique and image post-processing technique [8, 9]. In the second step (i.e., data analysis), models can be built upon either conventional statistical methods or machine learning algorithms with the aim of predicting the diagnosis or outcome of interest. In either case, the main challenge is model validation [9].
The challenges of reproducibility and validation strategies in radiomics have been recently addressed in a review focusing on renal masses [10]. The aim of our study is to systematically review radiomic feature reproducibility and predictive model validation strategies in studies dealing with CT and MRI radiomics of bone and soft-tissue sarcomas. The ultimate goal is to promote and facilitate achieving a consensus on these aspects in radiomic workflows.

Methods

Reviewers

No Local Ethics Committee approval was needed for this systematic review. Literature search, study selection, and data extraction were performed independently by two recently boarded radiologists with experience in musculoskeletal tumors and radiomics (S.G. and F.M.). In case of disagreement, agreement was achieved by consensus of these two readers and a third reviewer with radiology specialty and doctorate in artificial intelligence and radiomics (R.C.). The Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines [11] were followed.
An electronic literature search was conducted on EMBASE (Elsevier) and PubMed (MEDLINE, U.S. National Library of Medicine and National Institutes of Health) databases for articles published up to December 31, 2020, and dealing with CT and MRI radiomics of bone and soft-tissue sarcomas. A controlled vocabulary was adopted using medical subject headings in PubMed and the thesaurus in EMBASE. Search syntax was built by combining search terms related to two main domains, namely “musculoskeletal sarcomas” and “radiomics.” The exact search query was: (“sarcoma”/exp OR “sarcoma”) AND (“radiomics”/exp OR “radiomics” OR “texture”/exp OR “texture”). Studies were first screened by title and abstract, and then, the full text of eligible studies was retrieved for further review. The references of selected publications were checked for additional publications to include.

Inclusion and exclusion criteria

Inclusion criteria were: (1) original research papers published in peer-reviewed journals; (2) focus on CT or MRI radiomics-based characterization of sarcomas located in bone and soft tissues for either diagnosis- or prognosis-related tasks; (3) statement that local ethics committee approval was obtained, or ethical standards of the institutional or national research committee were followed.
Exclusion criteria were: (1) papers not dealing with mass characterization, such as those focused on computer-assisted diagnosis and detection systems; (2) papers dealing with head and neck, retroperitoneal or visceral sarcomas; (3) animal, cadaveric or laboratory studies; (4) papers not written in English language.

Data extraction

Data were extracted to a spreadsheet with a drop-down list for each item, as defined by the first author, grouped into three main categories, namely baseline study characteristics, radiomic feature reproducibility strategies, and predictive model validation strategies. Items regarding baseline study characteristics included first author’s last name, year of publication, study aim, tumor type, study design, reference standard, imaging modality, database size, use of public data, segmentation process, and segmentation style. Those concerning radiomic feature reproducibility strategies included reproducibility assessment based on repeated segmentations, reproducibility assessment related to acquisition or post-processing techniques, statistical method used for reproducibility analysis, and cut-off or threshold used for reproducibility analysis. Finally, data regarding predictive model validation strategies included the use of machine learning validation techniques, clinical validation performed on a separate internal dataset, and clinical validation performed on an external or independent dataset.

Results

Baseline study characteristics

A flowchart illustrating the literature search process is presented in Fig. 1. After screening 278 papers and applying our eligibility criteria, 49 papers were included in this systematic review. Tables 1 and 2 detail the characteristics of papers dealing with radiomics of bone (n = 12) and soft-tissue (n = 37) tumors, respectively.
Table 1
Characteristics of the papers dealing with bone sarcomas included in the systematic review
First author
Year
Aim
Tumor
Design
Reference standard
Modality
Database size (n)
Public data
Segmentation
Process
Style
Baidya Kayal [50]
2020
Therapy response
Osteosarcoma
Prospective
Histology
MRI
32
No
Manual
3D
Chen [29]
2020
Local relapse
Metastatic relapse
Osteosarcoma
Retrospective
Histology Imaging
MRI
93
No
Manual
2D without MS
Dai [45]
2020
Histotype
Ewing sarcoma Osteosarcoma
Retrospective
Histology
MRI
66
No
Manual
2D without MS
Fritz [13]
2018
Benign versus malignant
Grading
Chondroma Chondrosarcoma
Retrospective
Histology Imaging
MRI
116
No
Manual
2D without MS
Gitto [46]
2020
Grading
Chondrosarcoma
Retrospective
Histology
MRI
58
No
Manual
2D without MS
Li [32]
2019
Histotype
Chondrosarcoma Chordoma
Retrospective
Histology
MRI
210
No
Manual
3D
Lin [15]
2020
Therapy response
Osteosarcoma
Retrospective
Histology
CT
191
No
Manual
3D
Lisson [12]
2018
Benign versus malignant
Chondroma Chondrosarcoma
Retrospective
Histology Imaging
MRI
22
No
Semiautomatic
3D
Wu [16]
2018
Survival
Osteosarcoma
Retrospective
Follow-up
CT
150
No
Manual
3D
Yin [38]
2020
Local relapse
Chondrosarcoma
Retrospective
Histology Imaging
MRI
103
No
Manual
3D
Yin [28]
2019
Histotype
Chordoma
Giant cell tumor
Retrospective
Histology
CT
95
No
Manual
3D
Zhao [22]
2019
Survival
Osteosarcoma
Retrospective
Follow-up
MRI
112
No
Manual
3D
MS multiple sampling
Table 2
Characteristics of the papers dealing with soft-tissue sarcomas included in the systematic review
First author
Year
Aim
Tumor
Design
Reference standard
Modality
Database size (n)
Public data
Segmentation
Process
Style
Corino [52]
2018
Grading
Multiple sarcoma histotypes
Retrospective
Histology
MRI
19
No
Manual
3D
Crombé [39]
2020
Metastatic relapse
Survival
Liposarcoma
Retrospective
Histology Follow-up
MRI
35
No
Manual
3D
Crombé [42]
2020
Metastatic relapse
Survival
Multiple sarcoma histotypes
Retrospective
Histology Follow-up
MRI
50
No
Manual
3D
Crombé [30]
2019
Therapy response
Multiple sarcoma histotypes
Prospective
Histology Imaging
MRI
25
No
Manual
3D
Crombé [47]
2019
Therapy response
Multiple sarcoma histotypes
Retrospective
Histology
MRI
65
No
Manual
3D
Crombé [63]
2020
Therapy response
Survival
Liposarcoma
Retrospective
Histology Follow-up
MRI
21
No
Manual
3D
Crombé [36]
2020
Therapy response
Survival
Desmoid tumor
Retrospective
Imaging Follow-up
MRI
42
No
Manual
3D
Crombé [31]
2020
Metastatic relapse
Survival
Multiple sarcoma histotypes
Retrospective
Histology Follow-up
MRI
70
No
Manual
3D
Gao [33]
2020
Therapy response
Multiple sarcoma histotypes
Prospective
Histology
MRI
30
No
Manual
3D
Hayano [21]
2015
Survival
Multiple sarcoma histotypes
Prospective
Follow-up
CT
20
No
Manual
2D without MS
Hong [64]
2020
Grading
Multiple sarcoma histotypes
Retrospective
Histology
MRI
42
No
Manual
3D
Juntu [48]
2010
Benign versus malignant
Multiple benign/ malignant histotypes
Retrospective
Histology
MRI
135
No
Manual
2D with MS
Kim [65]
2017
Benign versus malignant
Multiple benign/ malignant histotypes
Retrospective
Histology
MRI
40
No
Manual
3D
Leporq [19]
2020
Benign versus malignant
Lipoma
Liposarcoma
Retrospective
Histology
MRI
81
No
Manual
2D without MS
Malinauskaite [23]
2020
Benign versus malignant
Lipoma
Liposarcoma
Retrospective
Histology
MRI
38
No
Semiautomatic
3D
Martin-Carreras [34]
2019
Benign versus malignant
Myxoma Myxofibrosarcoma
Retrospective
Histology
MRI
56
No
Manual
3D
Mayerhoefer [57]
2008
Benign versus malignant
Multiple benign/ malignant histotypes
Non-tumoral lesions
Retrospective
Histology
MRI
58
No
Manual
2D with MS
Meyer [66]
2019
Proliferation index
Multiple sarcoma histotypes
Retrospective
Histology
MRI
29
No
Manual
2D without MS
Peeken [25]
2019
Grading
Survival
Multiple sarcoma histotypes
Retrospective
Histology Follow-up
MRI
225
No
Manual
3D
Peeken [27]
2019
Grading
Survival
Multiple sarcoma histotypes
Retrospective
Histology Follow-up
CT
221
Yes
Manual
3D
Pressney [14]
2020
Benign versus malignant
Lipoma
Liposarcoma
Retrospective
Histology
MRI
60
No
Manual
2D without MS
Spraker [51]
2019
Survival
Multiple sarcoma histotypes
Retrospective
Follow-up
MRI
226
No
Manual
3D
Tagliafico [26]
2019
Local relapse
Multiple sarcoma histotypes
Prospective
Histology Imaging
MRI
19
No
Manual
2D with MS
Thornhill [49]
2014
Benign versus malignant
Lipoma
Liposarcoma
Retrospective
Histology
MRI
44
No
Semiautomatic
3D
Tian [35]
2020
Metastatic relapse
n/a
Retrospective
Histology Imaging
MRI
77
No
Manual
3D
Tian [67]
2015
Therapy response
Survival
Multiple sarcoma histotypes
Prospective
Histology Follow-up
CT
20
No
Manual
2D without MS
Timbergen [20]
2020
Histotype
Desmoid tumor
Multiple sarcoma histotypes
Retrospective
Histology
MRI
203
No
Manual
3D
Vallières [55]
2015
Metastatic relapse
Multiple sarcoma histotypes
Retrospective
Histology Imaging
MRI
51
Yes
Manual
3D
Vallières [68]
2017
Metastatic relapse
Multiple sarcoma histotypes
Retrospective
Histology Imaging
MRI
30
Yes
Manual
3D
Vos [40]
2019
Benign versus malignant
Lipoma
Liposarcoma
Retrospective
Histology
MRI
116
No
Semiautomatic
3D
Wang [41]
2020
Grading
Multiple sarcoma histotypes
Retrospective
Histology
MRI
113
No
Manual
3D
Wang [43]
2020
Benign versus malignant
Multiple benign/ malignant histotypes
Retrospective
Histology
MRI
206
No
Manual
3D
Wang [24]
2020
Benign versus malignant
Multiple benign/ malignant histotypes
Retrospective
Histology
MRI
91
No
Manual
3D
Wu [18]
2020
Benign versus malignant
Multiple benign/ malignant histotypes
Retrospective
Histology
CT
49
No
Manual
2D without MS
Xiang [17]
2019
Grading
Multiple sarcoma histotypes
Retrospective
Histology
MRI
67
No
Manual
2D without MS
Xu [37]
2020
Grading
Multiple sarcoma histotypes
Retrospective
Histology
MRI
105
No
Manual
3D
Zhang [44]
2019
Grading
Multiple sarcoma histotypes
Retrospective
Histology
MRI
37
No
Manual
3D
MS multiple sampling
All studies were published between 2008 and 2020. Twenty-three out of 49 investigations (47%) were published in 2020, 14 (29%) in 2019, 4 (8%) in 2018, and 8 (16%) between 2008 and 2017. The design was prospective in 6 studies (12%) and retrospective in the remaining 43 (88%). The imaging modality of choice was MRI in 42 (86%), including one or multiple MRI sequences, and CT in 7 (14%) cases. The median size of the database was 60 patients (range 19–226). Public data were used only in 3 (6%) studies.
The research was aimed at predicting either diagnosis or prognosis, as follows: benign versus malignant tumor discrimination (n = 14); grading (n = 10); tumor histotype discrimination (n = 4); proliferation index Ki67 expression (n = 1); survival (n = 12); response to therapy, either chemotherapy or radiotherapy (n = 8); local and/or metastatic relapse (n = 9). It should be noted that the aim was twofold in some studies, as detailed in Tables 1 and 2. In those focused on diagnosis-related tasks, including benign versus malignant discrimination, grading, tumor histotype discrimination, and proliferation index expression, histology was the reference standard in all cases excepting benign lesions diagnosed on the basis of stable imaging findings over time in two papers [12, 13]. In studies focused on prediction of response to chemotherapy or radiotherapy, the reference standard was histology if lesions were surgically treated, based on the percentage of viable tumor and necrosis relative to the surgical tissue specimen, or consistent imaging findings if lesions were not operated. In studies focused on prediction of tumor relapse, the diagnosis was based on histology or consistent imaging findings, as the reference standard. In studies dealing with survival prediction, survival was assessed based on follow-up.
Regarding segmentation, the process was performed manually in 45 (92%) studies and semiautomatically in 4 (8%) studies. In no case, the segmentation process was fully automated. The following segmentation styles were identified: 2D without multiple sampling in 11 (23%) studies; 2D with multiple sampling in 3 (6%); 3D in 35 (71%). Of note, a single slice showing maximum tumor extension was chosen in all studies employing 2D segmentation without multiple sampling, excepting one case [14] where it was chosen based on signal intensity homogeneity.

Reproducibility strategies

Eighteen (37%) of the 49 studies included a reproducibility analysis of the radiomic features in their workflow. In 16 (33%) investigations [13, 1529], the reproducibility of radiomic features was assessed on the basis of repeated segmentations performed by different readers and/or the same reader at different time points. Two (4%) studies presented an analysis to assess the reproducibility based on different acquisition [30] or post-processing [31] techniques. Of note, segmentations were validated by a second experienced reader in 15 studies [12, 3245] without, however, addressing the issue of radiomic feature reproducibility.
The intraclass correlation coefficient (ICC) was the statistical method used in most of the papers reporting a reproducibility analysis [13, 1518, 20, 2225, 2729, 31]. ICC threshold ranged between 0.6 [13] and 0.9 [22] for reproducible features. The following statistical methods were used less commonly: analysis of variance [30, 31]; Cronbach alpha statistic [26]; Pearson correlation coefficient [19], and Spearman correlation coefficient [21].

Validation strategies

At least one machine learning validation technique was used in 25 (51%) of the 49 papers. K-fold cross-validation was used in most of the studies [13, 25, 28, 3133, 37, 38, 40, 43, 44, 4650]. The following machine learning validation techniques were used less commonly: bootstrapping [42, 51]; leave-one-out cross-validation [34, 35, 41]; leave-p-out cross-validation [52]; Monte Carlo cross-validation [23]; nested cross-validation [25, 27]; random-split cross-validation [20]. Figure 2 provides an overview of machine learning validation techniques. Figure 3 illustrates an example of a radiomics-based machine learning pipeline.

Clinical validation

A clinical validation of the radiomics-based prediction model was reported in 19 (39%) of the 49 papers. It was performed on a separate set of data from the primary institution, i.e., internal test set, in 14 (29%) studies [15, 16, 22, 24, 28, 31, 32, 35, 37, 38, 41, 46, 47, 52]. It was performed on an independent set of data from the primary institution (related to a different scanner) or from an external institution, i.e., external test set, in 5 (10%) studies [25, 27, 29, 43, 51].

Discussion

This systematic review focused on the radiomics literature regarding MRI and CT of bone and soft-tissue sarcomas with particular emphasis on reproducibility and validation strategies. The number of papers reporting the assessment of radiomic feature reproducibility and the use of independent or external clinical validation was relatively small. This finding is in line with recent literature reviews showing that the quality of sarcoma radiomics studies is low [53, 54], which may hamper performance generalizability of radiomic models on independent cohorts and, consequently, their practical application [53]. Thus, these issues need to be addressed in the radiomic workflow of future studies to facilitate clinical transferability.

Baseline study characteristics

MRI and CT radiomics of bone and soft-tissue sarcomas have progressively gained attention in musculoskeletal and oncologic imaging. The number of papers has rapidly increased over the recent years, and almost half of those included in our review (47%) was published in 2020. Radiomics was used in attempt to answer clinical questions related to both diagnosis and prognosis of musculoskeletal sarcomas. Most studies (88%) were retrospective in nature, as this design allowed including relatively large number of patients with imaging data already available and bone or soft-tissue sarcomas, which are rare diseases. A prospective analysis, while not strictly necessary in radiomic studies [5], may, however, have advantages for controlling data gathering in reproducibility assessment and matching certain patient or imaging characteristics in independent datasets. Public data were used in no study regarding bone sarcomas and in a small proportion of the studies (6%) concerning soft-tissue sarcomas. A public database [55] available on The Cancer Imaging Archive (https://​www.​cancerimagingarc​hive.​net) was used in all these studies. Public databases afford opportunities for researchers who do not have sufficient data at their institution and allow research groups from around the world to test and compare new radiomic methods using common data. Thus, research employing radiomics in this field would certainly be enhanced if further imaging databases are made publicly available in the near future.
Regarding segmentation, the process was performed manually in most of the studies (92%) and semiautomatically in the remaining, both requiring human intervention to some extent. Even though the influence of inter-observer and/or intra-observer variability on the reproducibility of radiomic features can be assessed as part of the radiomic workflow, fully automated segmentation algorithms would ideally achieve higher reliability and deserve future investigation. Annotations included the entire lesion volume (3D segmentation) in most of the studies (71%) and a single slice (2D), without multiple sampling, in the remaining (23%). However, to date no study has compared the outcome of 2D and 3D segmentations in musculoskeletal sarcomas. As 2D annotations are time saving and have recently proven higher performance than 3D segmentation in oropharyngeal cancers [56], this should represent another area of research in the near future. Of note, a limited number of studies (6%) used a 2D segmentation style with multiple sampling as a data augmentation technique to increase the number of labeled slices [26, 48, 57]. This practice can be useful for an uncommon entity as musculoskeletal sarcomas but should be employed with care to avoid the introduction of bias in the final model. The inclusion of samples from the same case in both the training and test sets could lead to overly optimistic results.

Reproducibility strategies

A great variability in radiomic features has emerged as a major issue across studies and attributed to different segmentation, image acquisition, and post-processing approaches [4]. Therefore, methodological analyses are advisable prior to conducting radiomic studies in order to assess feature robustness and avoid biases due to non-reproducible, noisy features. This concept is in line with recent literature emphasizing the importance of reproducibility in artificial intelligence and radiology [58]. In our review, we noted that about one third of the included papers described a reproducibility analysis in their workflow. In this subgroup of papers, inter- and/or intra-reader segmentation variability was the main focus of the reproducibility analysis. Segmentation variability-related analyses outnumbered those addressing reproducibility issues due to image acquisition or post-processing differences, which were reported in one paper per each [30, 31]. This finding underlines that further research should deal with dependencies of radiomic features on image acquisition and post-processing. While these analyses may already be performed in retrospective series, when patients underwent more than one study in a short interval, prospective studies could facilitate the identification of reliable radiomic features within this domain. Finally, ICC was the statistical method used in most of the papers evaluating radiomic feature reproducibility. Of note, guidelines for performing and assessing ICC are available and can be followed to achieve consensus on the cutoff and threshold values [59].

Validation strategies

Proper validation of radiomic models is highly desirable to bridge the gap between concepts and clinical application [53]. Machine learning validation techniques are employed to avoid any information leak from the test to the training set during model development [60]. Resampling strategies can be extremely useful, especially with relatively limited samples of data, which may not be truly representative for the population of interest, with the aim of reducing overfitting and better estimating the performance of the radiomics-based predictive model on new data (i.e., the test set) [61, 62]. K-fold cross-validation was the most commonly used technique for this task in the studies included in this review.
Ideally, in both prospective and retrospective studies, a clinical validation of the model is performed against completely independent sets of data, i.e., the external or independent test set [4]. We found that clinical validation was performed against an independent dataset from the primary institution (using different scanners) or from a different institution only in a small number of studies (10%) included in this systematic review. More studies (29%) validated the model using a separate set of data from the primary institution, i.e., an internal test set. Therefore, future studies should be carried out in more than one institution and include external testing of the model with large and independent sets of data.

Limitations and conclusions

This study is limited to a systematic review of the literature, and no meta-analysis was performed due to the lack of homogeneity between studies in terms of objectives and subgroups of sarcoma with a rather limited number of papers per each objective and subgroup. Different metrics were also used, preventing us from providing an estimation of model performance for each objective. Furthermore, it was outside of the scope of the review to perform a formal assessment of the quality of each included study, as our focus was on reporting methodological data that can be in and of themselves quality indicators. Limitations notwithstanding, we reviewed the radiomics literature regarding bone and soft-tissue sarcomas with emphasis on the methodologic issues of feature reproducibility and predictive model validation. They varied largely among the included studies, and, in particular, no reproducibility analysis was provided in more than half the papers. Additionally, less than half the studies included a clinical validation, and only 10% used an independent dataset for this purpose. Thus, in order to bring the field of radiomics from a preclinical research area to the clinical stage, both these issues should be addressed in future studies dealing with musculoskeletal sarcomas.

Declarations

Not applicable.
Not applicable.

Competing interests

The authors declare that they have no competing interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
36.
Metadaten
Titel
CT and MRI radiomics of bone and soft-tissue sarcomas: a systematic review of reproducibility and validation strategies
verfasst von
Salvatore Gitto
Renato Cuocolo
Domenico Albano
Francesco Morelli
Lorenzo Carlo Pescatori
Carmelo Messina
Massimo Imbriaco
Luca Maria Sconfienza
Publikationsdatum
01.12.2021
Verlag
Springer International Publishing
Erschienen in
Insights into Imaging / Ausgabe 1/2021
Elektronische ISSN: 1869-4101
DOI
https://doi.org/10.1186/s13244-021-01008-3

Weitere Artikel der Ausgabe 1/2021

Insights into Imaging 1/2021 Zur Ausgabe

PET kann infarktgefährdete Koronararterien entdecken

04.06.2024 Koronare Herzerkrankung Nachrichten

Der Nachweis aktiver Plaques mittels 18F-Natriumfluorid-PET hilft nicht nur, infarktgefährdete Patienten, sondern auch infarktgefährdete Koronararterien zu erkennen. Von einer gezielten Behandlung vulnerabler Plaques ist man trotzdem weit entfernt.

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.